Cleveland Clinic receives two grants totaling $4.6m to study cancer drug in Alzheimer's
(Cleveland Clinic) The National Institute of Aging (NIA), part of the National Institutes of Health (NIH), and the Alzheimer's Drug Discovery Foundation (ADDF) awarded five-year grants of $3.2 million and $1.4 million, respectively, to scientists from Cleveland Clinic Lou Ruvo Center for Brain Health to study the therapeutic potential of the anti-cancer drug lenalidomide in early-stage Alzheimer's disease, known as mild cognitive impairment (MCI).
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news
More News: Alzheimer's | Brain | Brain Cancers | Cancer | Cancer & Oncology | Grants | International Medicine & Public Health | National Institutes of Health (NIH) | Neurology | Revlimid | Study